Articles

  1. Brochure: RHOBUST® Downstream Processing Technology 2/22/2012
    Rhobust® technology is a downstream processing technology for the manufacturing of recombinant proteins and antibodies.
  2. Brochure: XD® Technology: Improve Biopharmaceutical Production 2/22/2012
    DSM's XD® Technology has been developed to drive yield improvements in the production of biopharmaceuticals.
  3. Brochure: Finished Dosage Forms 2/21/2012
    DSM is a global provider of finished dosage form manufacturing and related services to pharmaceutical and biopharmaceutical markets.
  4. PRA Exceeds Tough Enrollment Goals: Service Delivery Model Drives Positive Results 2/20/2012

    Changes in resources for both the client and PRA teams led to significant challenges with the start-up and enrollment activities in Europe and North America.

  5. Brochure: Biologics Contract Manufacturing & Technology Solutions 1/30/2012

    DSM provides turn-key biologic manufacturing solutions, contract manufacturing for preclinical development, clinical trials or commercial supply and reduced cost, risk, and time to market.

  6. Brochure: Pharma Sterile Dosage Forms 1/30/2012

    DSM offers pharmaceutical and biopharmaceutical customers a lyophilization system with unique benefits. It has the precision to serve increasingly demanding lyophilization cycles, a critical requirement for successful product launches and high commercial yields. 

  7. MTOSoftgels: Providing Cohort Specific Hand Filled Softgel Capsules For Dose Escalation Studies 11/2/2011

    Formulation and automated manufacture of capsules for early phase dose escalation clinical trials can be costly and wasteful. By Lisa Z Crandall

  8. Alkermes Contract Pharma Services 9/28/2011

    With Alkermes Contract Pharma Services, you have the opportunity to outsource your development, scale-up and manufacturing requirements to a trusted, experienced and dedicated expert in outsourcing services.

  9. Clinical Trials In Russia 8/26/2011
    The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) and the Ministry of Health and Social Development of the Russian Federation (MoH) approved 492 new clinical trials of all types including local and bioequivalence studies during 2010, demonstrating a 15% decrease from the last year figure.
  10. TQT Solutions 5/11/2011
    The increasingly complex regulatory environment has focused an intense spotlight on cardiac safety. You now have to produce more evidence with greater accuracy for the full spectrum of therapeutic areas.